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Aim: The aim of this study was to present one center experience in applying the SNOLL
technique to patients with suspected occult breast lesions.
Background: In the last years, the widespread use of mammographic screening programs
resulted in an increasing number of women with nonpalpable suspicious breast lesions
requiring further examination. The new method called sentinel node and occult lesion
localization (SNOLL) enables the intraoperative detection of nonpalpable breast tumors and
sentinel node biopsy in one surgical procedure.
Materials and methods: 46 patients with suspected malignant lesions or diagnosed non-
palpable breast cancer were subjected to a pre-operative SNOLL procedure. The day before
the surgery, theywere administered two radiotracers: one to localize the tumor and the other
to localize the sentinel node. During the surgery, the breast tumor and the sentinel node,
which in most cases had been examined intraoperatively, were detected with a handheld
gamma probe and resected under its control.
Results: All 46 (100%) patients had their occult breast lesions resected. Histopathologic exam-
ination revealed cancer in 40 patients: in situ in 2 cases, invasive in 38 cases. All these
patients had their sentinel nodes examined. In one case only, the sentinel node could
not be located with a gamma probe. Intraoperative tests showed the sentinel node to be
metastatic in 5 patients, who were then given a simultaneous axillary lymphadenectomy.
In addition, the ﬁnal histopathologic examination revealed metastasis to the sentinel node
in one patient, who had to be reoperated.
Conclusion: SNOLL is a modern technique that enables a precise intraoperative localizationof non-palpable suspected malignant breast lesions in combination with a sentinel node
biopsy. Extended application of intraoperative management leads to signiﬁcant decrease in
the number of reoperations performed in patients with early bread cancer.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.∗ Corresponding author. Tel.: +48 61 8850600; fax: +48 61 8850601.
E-mail address: adamczykb@yahoo.com (B. Adamczyk).
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the form of a hot spot (Fig. 1). A handheld gamma probe was
used during the surgery (Neoprobe 2000, Johnson&Johnson)
to localize the non-palpable breast lesion and the sentinel
node, as well as to guide the procedure (Fig. 2). During222 reports of practical oncology an
1. Background
Recently, a considerable growth in the number of diagnosed
cases of early breast cancer has been observed. This has
become possible mainly because of the larger availability
of screening assays, prevention programs, and changes in
women’s awareness of and approach towards the disease.
Owing to the development of imaging and biopsy techniques,
neoplastic lesions of the breast can now be detected at a very
early stage, before becoming clinically palpable. In such cases
modern medicine offers breast conserving therapy (BCT), an
option providing patients a signiﬁcant improvement in their
comfort and quality of life.
Today, BCT often involves quadrantectomy with a
sentinel node biopsy, supplemented by an appropriate
post-operative procedure, i.e. radiotherapy with or with-
out systemic treatment. This type of management often
ensures good cosmetic results with minimum surgical
intervention.1–3
The main issue with non-palpable breast lesions, which
represent 30% of diagnoses, is to localize them precisely
enough to be able to perform a correct excision with an ade-
quate margin of healthy tissues, while limiting the extent
of the surgical procedure from being too extensive. There-
fore, efforts are being made to develop a method to permit
this kind of precise localization.1 Currently, most commonly
used is the needle localization technique employing wires
that are inserted into breast lesions under mammographic or
ultrasound guidance. This method, however, is marked with
several important drawbacks. The very process of inserting
a needle into the breast is time consuming, often painful
and unpleasant. The wire is likely to be displaced, partic-
ularly in breasts with a predominant fatty component.3,4
It may also cause injuries both to the patient and to the
medical staff engaged. A surgeon resecting a lesion fol-
lows a needle-marked track, thus removing a wide range of
healthy tissues and undermining the cosmetic effect of the
procedure.4
A new method for the localization of occult breast lesions
has been developed in recent years. Radio-guided occult
lesion localization (ROLL) was ﬁrst proposed in 1997 in the
European Institute of Oncology, Milan, Italy.1,2 It involves
intratumoral injection of a radiotracer under mammographic
and ultrasound guidance. The injection site is located intra-
operatively by means of a handheld gamma camera which
also enables controlled dissection of the lesion.1 ROLL may
therefore be used as a diagnostic and therapeutic method
for occult breast tumors. A great deal of research has
proved this method to be superior to the commonly used
guidewires.3,5
When a non-palpable early breast cancer is recognized
preoperatively, the status of regional lymph nodes has to
be determined. This is made possible by a sentinel node
biopsy, which is an optional method in such cases.1 The
application of both ROLL and SNB within one surgical ses-
sion has given rise to the development of SNOLL (sentinel
node and occult lesion localization), ﬁrst described and
performed in Milan’s European Institute of Oncology in
1998.1,2iotherapy 1 6 ( 2 0 1 1 ) 221–226
2. Aim
The aim of this study is to present our experience in the use
of SNOLL technique in patients with occult malignant breast
tumors which were qualiﬁed for breast conservative surgery.
3. Materials and methods
Forty-six female patients aged 41–78 (mean age: 59) were sub-
jected to the SNOLL procedure between May 2008 and May
2009.
All the patients had been diagnosed to have a solitary,
non-palpable breast cancer and suspected malignant breast
lesions revealed by ultrasonography and/or mammography.
They had been ranked 4–5 in the BI-RADS scale and classiﬁed
as T1 (size≤20mm). Clinical examination had not indicated
any suspected axillary lymph nodes. 36 women had been pre-
operatively diagnosed with early breast cancer, as based on
cytologic examination (22) and a thick-needle biopsy (29). In
the patients diagnosed with stereotactic biopsy, the breast
area after the procedure had been marked with a titanium
clip which could be detected by ultrasound within 4–6 weeks
post-implantation. In the case of 10 patients with suspected
malignant lesions, it was necessary to perform an intraoper-
ative examination of frozen specimens resected by means of
ROLL. Patients with proven cancer were given a sentinel node
biopsy to obtain specimens for intraoperative histopathologic
assessment. Informed consentwas obtained fromall patients.
Two types of radiotracers (99mTc) were used in the SNOLL
procedure:
1. human albumin macroaggregates (MAA), with particles
sized 10–150m, used in the ROLL procedure. This is an
immobile radiotracer that remains in the site of the injec-
tion (MAASOL, GE Healthcare);
2. human albumin nanocolloid (NC), with particles sized
10–80nm which is used in the SNB procedure. This is a
mobile radiotracer that migrates through lymphatic con-
duits from the injection point to the sentinel node, where
it accumulates (Nannocol, GE Healthcare).
Radiotracers were prepared by the Nuclear Medicine
Department in single doses of 99mTc-MAA of 15–20MBq
diluted in 0.2ml saline and 99mTc-NC of 37MBq diluted in
0.5–0.7ml saline (volume depending on the size of the breast).
Tracers were inserted one day before the planned surgery
under ultrasound guidance (line probe of 7.5–10MHz) in coop-
erationwith a radiologist responsible for the localization of the
breast lesion. First, an intratumoral 99mTc-MAA injection was
made, followed by an intracutaneous 99mTc-NC injection at a
site located above the tumor. A lymphoscintigraphy was per-
formed the following day, before the surgery, usually 16–22h
after the tracer implantation. A frontal scan exposed the tracer
injection sites in the breast and the axillary sentinel node(s) in
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Fig. 1 – Lymphoscintigraphy (the big spot – the site of tracer
injections, the small spot – the sentinel lymph node).
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Fig. 3 – Intraoperative tumor localization using a gamma
probe (ROLL).
Table 1 – Histopathological diagnosis of resected breast
lesions.
Diagnosis Number of patients %
Benign lesions 6 13
Cancer 40 87
Non-invasive cancer
DCIS 2 9
LCIS 0 0
Invasive cancer
Ductal 24 63
Ductal and in situ 9 24uadrantectomy, the skin on the breast was cut right above
he hot spot indicated by the probe (Fig. 3). A specimen thus
eceived was evaluated intraoperatively by means of a radio-
ram and histopathologic examination (type of tumor, size
f cancer-free margins). When the pathologist reported the
argin to be uncertain or too small, the surgeon responded
mmediately by re-excision of a concerned area of the breast.
o be deemed sufﬁcient, the margin had to be at least 0.5 cm
ide or clear from the side of the breast muscle and/or
kin. Patients with conﬁrmed breast cancer were addition-
lly treated with a sentinel node biopsy. Resected specimens
f the sentinel node were also subjected to intraoperative
istopathologic assessment. If metastasis was found, the
atient underwent a concurrent lymphadenectomy.
. Resultson-palpable breast tumors were successfully localized intra-
peratively and fully resected in all 46 patients.
ig. 2 – Gamma probe for detecting “hot spot” of the breast
umor and the sentinel node.Lobular 2 5
Other 3 8
Total 46 100
The ﬁnal histopathologic examination revealed invasive
cancer in 38 patients, cancer in situ in 2 patients, and benign
lesions in 6 patients (Table 1).
The average size of a ROLL-localized tumor was 12mm
(range 4–21mm in ﬁnal pathological examination). The
median volume of excised specimens was 79.55±42 cm3. In
95% of cases, malignant breast lesions were removed with
negative surgical margins (Table 2).Sentinel node biopsies were performed in all 40 patients
with diagnosed breast cancer. An average of 1.7 of sentinel
node was resected. The sentinel node could not be located
Table 2 – Margins after quadrantectomy.
Diagnosis Number of
patients
% Radicalization
Clear margins 30 75 None
Small
margins
(≤4mm)
8 20 Intraoperative
(margin
extension)
Involved
margins
2 5 Post-operative
(mastectomy/
reexcision)
Total 40 100
224 reports of practical oncology and rad
Table 3 – Sentinel node status assessment in 40 patients.
Number of patients %
Metastatic 5 12
Non-metastatic 35 88
Lymphadenectomy
particles of nanocolloid (Nanocoll, GE Healthcare, Italy) canSimultaneous 4 80
Second surgery 1 20
in one patient. In this case the axillary nodes dissection
was performed. In 4 invasive cancer patients, metastasis
to the sentinel node was recognized during intraoperative
examination. These patients were treated with axillary lym-
phadenectomy within the same surgical session. The ﬁnal
post-surgery histopathologic examination revealed neoplastic
cells in the sentinel node in another patient, who underwent
a second operation. Data concerning the sentinel node are
presented in Table 3.
5. Discussion and conclusions
Recently, a growth in the number of diagnosed early breast
cancers has been observed due to the increased availability of
imaging examinations anddisease prevention programs.Now,
it is necessary to develop a reliable, safe and patient-friendly
method of localizing non-palpable lesions. The SNOLL proce-
dure, currently applied in some European oncology centers,
has already been recognized as an important component of
breast conservative therapy.1–3 In our department, the ROLL
and SNB techniques are applied to patients with diagnosed
early breast cancer. There are two reasons for that. First, with
a lesion being usually small in size and clinically impalpa-
ble, the main task of a surgeon is to cut it out precisely, with
an adequate margin of healthy tissues, which can be best
achieved by the ROLL technique.7–9 Besides, as small malig-
nant tumors pose a relatively low risk of metastasis to the
axillary lymph nodes, their complete excision often proves
unnecessary. Therefore, the widely accepted method of sen-
tinel node biopsy is particularly advisable in early stage breast
cancer.10 With selected patients of our center, we resort to
a modern approach involving concurrent application of both
techniques. The SNOLL procedure is being used in a variety of
ways, depending on the experience of a medical center.
Treatment of occult breast cancer aims primarily at its
precise resection together with an appropriate margin of sur-
rounding tissues. More and more emphasis is being put on
preventing unnecessary removal of healthy tissues and on
improvement of the post-operative cosmetic effect. There-
fore, efforts are being made to develop techniques enabling
precise pre-operative and intraoperative localization of occult
breast lesions. There are several methods that are currently
in use for this purpose, e.g. skin marking with USG, intra-
operative US, carbon localization or, most commonly applied,
wire-guided localization (WGL). Most of these methods, how-
ever, are characterized by insufﬁcient accuracy. The standard
technique, used inmany cancer therapy centers, involves nee-
dles of various shapes and sizes inserted into the suspected
breast area. Theneedles are usually implantedunder the guid-
ance of stereotactic mammography. While this method offersiotherapy 1 6 ( 2 0 1 1 ) 221–226
some obvious beneﬁts, it also has a number of important
weaknesses. The injection itself is rather traumatic and lon-
glasting. Needles being inserted into a patient’s breast may
cause pain and bleeding. There is no practical way to adjust
the position of a wire after it has been placed incorrectly. In
breasts with a predominant fatty component there is a risk
of needle displacement and consequent failure to collect a
specimen or resect the whole of a tumor. On the other hand,
breasts with a predominant glandular component are more
difﬁcult for implanting a wire.3 The ROLL method is a way
to avoid all the disadvantages of the wire-guided procedure,
while providing the beneﬁts of precise localization and access
to the center of an occult breast lesion. It is a low-invasive,
fast, and thus patient-friendly method of tracer implantation.
There is a larger rate of clear margins of resected specimens,
resulting in a lower rate of reoperations. There is more conve-
nience of use and a better resection spacial control offered by a
hand-held gammaprobe. Finally, the lower volume of resected
breast glandmeans a signiﬁcant improvement in the cosmetic
effect.11
Many comparative studies of the needle method and the
ROLL technique have been conducted in recent years. Results
clearly indicate the superiority of the latter.3–5,11 Indeed, in
terms of resection radicality, the ROLL method has brought
about a substantial reduction in the rate of reoperations.12
Nadeem et al. stated in their study that clear margins were
found in 83%of patients treatedwith ROLL versus 57%of those
treated with needle localization.11 Medina-Franco et al. indi-
cated proportions of 87.5% and 62.5% for the ROLL and the
wire-guided methods, respectively.13 The multi-center, ran-
domized clinical study published by van Esser et al. showed a
15% advantage in the rate of clear margins achieved by ROLL.9
Similar differences can be derived froma comparison between
the sizes of breast specimens resectedwith the aid of ROLL and
WGL. The studies made by Nadeem et al. or Mariscal-Martinez
et al. did not show any statistically signiﬁcant differences in
the volume and weight of the specimens.11,14 Zgajnar et al., on
the other hand, demonstrated a lower mean weight of breast
specimens resected with the ROLL technique (40 g and 53g for
ROLL and WGL, respectively).15 The post-operative cosmetic
effect was also compared. ROLL patients rated the effect as
very good in 75% and good 25%, while WGL patients rated it
as very good in 54% and good in 46%.11,13 Both methods were
also compared in terms of patient’s discomfort during proce-
dures, the costs and time required, the level of difﬁculty, and
the rate of sentinel node identiﬁcation. The studies and anal-
yses deﬁnitely conﬁrm the radioguided method to be more
beneﬁcial.3,5,9,11,13–15
The original SNOLL method, developed by the European
Institute of Oncology (EIO), Milan, in 1997, which combines
the ROLL technique with a sentinel node biopsy, employs
two types of Technetium Tc99m carriers. Human albumin
macroaggregates (Maasol, GE Healthcare, Italy) have particles
large enough not to be drained by lymph vessels around the
tumor and therefore stay at the site of injection, clearly indi-
cating the location of a non-palpable breast lesion. Smallerin turn easily penetrate into the lymph vessels and move
freely to the sentinel node, where they accumulate to make
it detectable.1,2,10 In our department, we have introduced the
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riginal method of EIO. Other centers which have adopted
NOLL have developed their own variants of the method.
Studies published in recent years have shown comparable
ffects of applying the SNOLLmethodwith a single radiotracer
2,16,17. Feggi et al. proposed the use of a nanocolloid labeled
ith Technetium-99m (NC-Tc99m) of 0.3–0.4ml for simulta-
eous performance of ROLL and sentinel node identiﬁcation.
ne day before surgery, half of the dose was injected intra-
umorally and half superﬁcially, but very close to the tumor.
he procedure was 100% effective in permitting the excision
f occult breast lesions and 97.3% effective in permitting the
ocalization of the sentinel node. The authors of the study
tressed that the single tracermethod is a useful option in that
t saves time and costs, as well as facilitates the procedure.16
imilar conclusions were drawn by Lavoue et al., who only
njected technetium-labeled nanocolloid peritumorally: 0.2ml
bove and 0.2ml below the tumor.12 Although all patients had
heir non-palpable breast lesions removed, the sentinel node
dentiﬁcation rate of 90% was not fully satisfactory, calling for
urther improvement of the technique.16
The single tracermethodalsohas the inconvenience of fail-
ng to determine the exact scope of radioactivity for a certain
roup of patients. This may result from the broadening of the
ignal emitted from two insertion sites located close to each
ther and nanocolloid migration to adjacent lymph vessels.
evertheless, most of the studies referred to in this article
onﬁrm the feasibility of a single radiopharmaceutical in the
NOLL technique. This is certainly a way to facilitate the pro-
edure, while reducing the time and costs needed to perform
t.12,16,17
Another disputable issue regarding SNOLL is where to
nject a radiopharmaceutical to achieve the best possible
dentiﬁcation of the sentinel node. Studies concerning sen-
inel node localization have proposed a large variety of
ossible locations for injecting Tc99 nanocolloid. The most
requently described are: intratumoral, peritumoral, subder-
al/intradermal and periareolar/subareolar injections.10
In our study, we followed the experience of the European
nstitute of Oncology by administering a tracer intradermally
ith a typical bubble on the skin right above the tumor, at a
oint marked by a radiologist with a felt-tip pen. We did not
pply additional patent-blau staining, relying on our own long
xperience in sentinel node biopsy and so as to avoid possi-
le tattoos that clearly deteriorate the post-operative cosmetic
ffect. Utilizing this method, we achieved 98% sentinel node
dentiﬁcation. Barros et al. conﬁrmed in their study that a com-
ination of two tracers – radioisotope and patent-blau – in a
edical center having extensive experience in the application
f radioisotopic techniques does not produce signiﬁcant ben-
ﬁts with respect to sentinel lymph node identiﬁcation.18 It
as to be assumed that in a certain number of cases the sen-
inel node simply cannot be localized. The reasons for this
ay be the variable anatomy and size of the breast, block-
ge of a lymph vessel, massive invasion of neoplastic cells
nto the lymph node, or even incorrect preparation of radio-
harmaceuticals or an inadequate time interval between the
racer injection and the surgery. With some of these possi-
le factors being beyond control, the sentinel node remains
ndetectable in a small percentage of patients despite proper
mplementation of the method.10therapy 1 6 ( 2 0 1 1 ) 221–226 225
The study by de Cicco demonstrates a higher rate of
sentinel node localization with Tc99m-labeled nanocolloid
injected subdermally (98.8%) as compared to peritumoral
injection (80.6%) and intratumoral injection (88.6%).2 Oppo-
site results were published by Feggi, who recorded a higher
rate of sentinel node identiﬁcation after injecting a radio-
tracer in the immediate vicinity of the tumor.16 Patel, apart
from 99mTc-nanocolloid, performed a periareolar intrader-
mal/subcutaneous injection of patent blue-V dye in order to
optimize sentinel node localization.19 Out of many possible
nanocolloid injection sites proposed by multiple studies, the
periphery of the tumor seems to be the most advisable loca-
tion. Further research in this area is necessary though, as
ﬁndings regarding sentinel node identiﬁcation in the SNOLL
method vary across centers.
The radioisotopic method, with all its beneﬁts, is beyond
any doubt an interesting alternative to the needle technique,
which is still regarded as a standard approach. Our study con-
ﬁrms that the SNOLL technique allows an exact intraoperative
localization of clinically occult breast cancer and the sen-
tinel node within one surgical session. The method enables
a precise and fast excision of a breast tumor with a mini-
mum necessary margin of healthy tissue. Reoperations forced
by positive margins had to be performed in 5% of patients
only. The simultaneous intraoperative performance of a sen-
tinel node biopsy and sentinel node status assessment in
patients with conﬁrmed cancer has also largely contributed
to the reduction of necessary reoperations. The results of this
study have encouraged us to use SNOLL in our department’s
everyday practice as a method of effective therapy for early
non-palpable breast cancer.
At present however, its widespread development is some-
what restricted by factors such as limited access of breast
cancer treatment centers to nuclear medicine facilities. Many
authors also emphasize that good cooperation between the
radiologist, the nuclear medicine physician and the surgeon
is a necessary condition for optimal utilization of the SNOLL
method.13 Considering that the current approach to early
breast cancer treatment is targeted towards minimalization of
patients’ discomfort and injury, it seems that general imple-
mentation of the SNOLL technique is just a matter of a short
time and the proper organization of breast units.
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